How should metabolic dysfunction‑associated steatotic liver disease (MASLD) / metabolic dysfunction‑associated steatohepatitis (MASH) be assessed using non‑invasive fibrosis scores, and what lifestyle interventions and emerging pharmacologic therapies are recommended?

MASLD & MASH: Non-invasive Fibrosis Assessment, Lifestyle Interventions, and Pharmacotherapy

All adults with MASLD should undergo initial risk stratification using FIB-4 score, followed by vibration-controlled transient elastography (VCTE) or Enhanced Liver Fibrosis (ELF) testing for indeterminate or elevated scores, with lifestyle modification as the cornerstone of treatment and resmetirom or semaglutide reserved for non-cirrhotic MASH patients with stage F2-F3 fibrosis. 1, 2

Non-invasive Fibrosis Assessment: The Two-Step Approach

Step 1: FIB-4 Score as Initial Screening

Begin with FIB-4 calculation (age, AST, ALT, platelet count) for all MASLD patients 1, 3:

• FIB-4 <1.3 (or <2.0 if age >65): Low risk for advanced fibrosis. Repeat FIB-4 every 2-3 years with continued lifestyle intervention 1

  • Critical caveat: FIB-4 will miss approximately 10% of individuals with advanced fibrosis, so clinical vigilance remains essential 1

• FIB-4 1.3-2.67: Indeterminate risk. Two management options 1:

  1. Proceed directly to elastography (preferred if FIB-4 closer to 2.67 or high-risk conditions present)
  2. Implement 1-year intensive lifestyle intervention with cardiometabolic optimization, then retest FIB-4; if still elevated, proceed to elastography

• FIB-4 >2.67: High risk. Proceed immediately to Step 2 1

Step 2: Elastography or Blood Biomarkers

For patients with indeterminate or elevated FIB-4 1, 3, 4:

• VCTE (FibroScan): Most accessible second-line test

  • <8 kPa: Minimal/no fibrosis
  • 8-15 kPa: Significant fibrosis (F2-F3) - treatment candidates
  • 15-20 kPa: Possible compensated cirrhosis - requires additional confirmatory testing

  • 20 kPa: Advanced cirrhosis

• MRE (Magnetic Resonance Elastography): More accurate but less accessible

  • <3.1 kPa: Minimal fibrosis
  • 3.1-4.4 kPa: Significant fibrosis (F2-F3) - treatment candidates
  • 4.4-5.0 kPa: Possible cirrhosis

  • 5.0 kPa: Cirrhosis

• ELF (Enhanced Liver Fibrosis) test: Blood-based alternative 1, 2

  • <9.2: Low risk
  • 9.2-10.5: Significant fibrosis (F2-F3) - treatment candidates

  • 10.5: Advanced fibrosis/cirrhosis

Important limitation: None of these methods assess steatohepatitis activity (ballooning, lobular inflammation), only fibrosis 1. However, liver biopsy is not required for clinical management in most cases 1.

Lifestyle Interventions: The Foundation of All Treatment

Weight Loss Targets

For patients with overweight or obesity, target 7-10% weight loss 1, 3, 5:

• Even 5% weight loss improves steatosis
• 7-10% weight loss improves steatohepatitis and may reduce fibrosis
• Weight loss benefits apply even to normal-weight individuals with MASLD 1

Dietary Recommendations

Mediterranean diet is the preferred dietary pattern 1, 5:

• Emphasize whole grains, vegetables, fruits, legumes, nuts, olive oil
• Reduce refined carbohydrates and saturated fats
• Hypocaloric approach (500-1000 kcal/day deficit) for those with excess weight 3, 6

Evidence caveat: While diet quality improvements reduce steatosis, robust evidence for impact on liver-related clinical outcomes remains limited 1

Physical Activity

Prescribe ≥150 minutes/week of moderate-intensity or 75 minutes/week of vigorous-intensity aerobic activity 1, 3:

• Reduces steatosis independent of weight loss
• Provides substantial cardiometabolic benefits
• Should be tailored to individual preference and ability

Evidence note: Benefits on histological outcomes and liver-related clinical outcomes are less robust than cardiometabolic benefits 1

Alcohol and Smoking

• Complete alcohol abstinence for patients with significant fibrosis (≥F2) 5
• Limited alcohol intake (<140 g/week for women, <210 g/week for men) acceptable for mild/no fibrosis 3
• Smoking cessation recommended for all patients regardless of fibrosis stage 5

Coffee Consumption

Coffee consumption has been associated with improvements in liver damage and reduced liver-related outcomes in observational studies, though this is not a formal recommendation 1

Pharmacological Therapy: Evidence-Based Treatment Algorithm

For Non-Cirrhotic MASH with F2-F3 Fibrosis

Two FDA-approved options exist, both with strong evidence 1, 2:

Option 1: Resmetirom (Thyroid Hormone Receptor β Agonist)

Primary MASH-targeted therapy for non-cirrhotic patients with stage F2-F3 fibrosis 1:

• Demonstrated histological efficacy on both steatohepatitis and fibrosis in large phase III trial
• Acceptable safety and tolerability profile
• Critical limitation: Long-term outcome data, sustainability of benefits, and individual response prediction not yet available 1

Option 2: Semaglutide 2.4 mg/week (Wegovy® formulation)

FDA-approved in August 2025 for MASH with F2-F3 fibrosis based on ESSENCE trial 2:

• 72-week data showed MASH resolution in 62.9% vs 34.3% placebo (p<0.001)
• ≥1 stage fibrosis reduction in 36.8% vs 22.4% placebo (p<0.001)
• Accelerated approval pending long-term outcomes

Patient selection for semaglutide 2:

• Use NITs (VCTE 8-15 kPa, MRE 3.1-4.4 kPa, ELF 9.2-10.5) rather than biopsy
• For borderline cirrhosis range (VCTE 15-20 kPa, MRE 4.4-5.0 kPa, ELF 10.5-11.3): individualize decision after excluding cirrhosis with confirmatory NIT, imaging, or platelet count >150,000/mm³

Monitoring semaglutide treatment response at 72 weeks 2:

• Significant improvement suggested by: ALT reduction >17 U/L or ≥20%; CAP reduction ≥30%; VCTE LSM reduction ≥30%; MRE LSM reduction ≥20%; ELF reduction ≥0.5
• Non-response suspected if ALT or NITs worsen

Safety monitoring for semaglutide 2:

• Most common: GI symptoms (nausea, diarrhea, constipation, vomiting) - usually mild and transient
• Serious but rare: acute kidney injury (from dehydration), gallbladder disease, pancreatitis, thyroid C-cell tumors, retinopathy progression, lean mass loss
• Routine hepatic panels only as clinically indicated (favorable hepatic safety profile)

For Patients with Type 2 Diabetes and MASLD

GLP-1 receptor agonists should be used for their diabetes indication 1, 7:

• Safe in MASH including compensated cirrhosis
• Improve cardiometabolic outcomes
• Cannot be recommended as MASH-targeted therapy due to lack of formal histological improvement demonstration in large phase III trials 1
• Substantial weight loss from GLP-1RAs may provide hepatic histological benefit, though not extensively documented 1

SGLT2 inhibitors should be used for diabetes, heart failure, or CKD indications 1, 7:

• Safe in MASLD
• Insufficient evidence as MASH-targeted therapy
• Provide established cardiorenal benefits

Metformin: Insufficient evidence as MASH-targeted therapy; use for diabetes indication 1

Agents NOT Recommended as MASH-Targeted Therapy

Vitamin E: Cannot be recommended despite some historical use 1:

• Lacks robust demonstration of histological efficacy in large phase III trials
• Potential long-term risks

Pioglitazone: Cannot be recommended as MASH-targeted therapy 1:

• Safe to use in non-cirrhotic MASH for diabetes indication
• Lacks robust phase III trial demonstration of histological efficacy

Nutraceuticals: Cannot be recommended 1:

• Insufficient evidence of effectiveness
• Safety concerns

For Cirrhotic MASH

No MASH-targeted pharmacotherapy currently recommended 1:

• Patients with compensated cirrhosis receiving GLP-1RAs for other indications should be monitored carefully
• Semaglutide not approved for cirrhotic patients, though those already on it for other indications require careful monitoring 2

Surgical Considerations

Bariatric surgery should be considered for MASLD patients with BMI >35 unresponsive to lifestyle and medical interventions 5, 6:

• Effective particularly for obese patients with advanced disease
• Gastric bypass and sleeve gastrectomy both effective

Monitoring and Follow-up Strategy

For Low-Risk Patients (FIB-4 <1.3)

• Repeat FIB-4 every 2-3 years 1
• Continue lifestyle interventions
• Optimize cardiometabolic risk factors

For Patients on Pharmacotherapy

• Cardiovascular risk assessment remains crucial - cardiovascular disease is the leading cause of death in MASLD 5, 6
• Monitor for diabetes development and optimize glycemic control 5
• Hepatocellular carcinoma screening for all cirrhotic patients; consider for advanced fibrosis based on individual risk 5

Dynamic Monitoring with NITs

Longitudinal changes in FIB-4, APRI, NFS, and elastography values correlate with fibrosis progression and can guide treatment intensification 1, 8

Critical Clinical Pitfalls to Avoid

1. Do not rely solely on FIB-4: It misses ~10% of advanced fibrosis cases 1
2. Do not use CT scans for steatosis assessment: Only provides rough estimate, not suitable for proper assessment 1
3. Do not combine resmetirom with semaglutide 2.4 mg/week: Not studied 2
4. Do not neglect cardiometabolic optimization: Cardiovascular disease, not liver disease, is the leading cause of death 5, 6
5. Do not perform routine liver biopsies: NITs are sufficient for clinical management in most cases 1